International Liver Cancer (ILCA) 2026 Annual Conference: Younger Age and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with Camrelizumab +
Rivoceranib vs Sorafenib (CARES-310)
ESMO 2024: Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis to Assess the Impact of Treatment With Camrelizumab + Rivoceranib (cam+rivo)
on Quality of Life vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: Study CARES-310
52nd Annual Meeting of Korean Cancer Association: Post hoc analysis of efficacy and safety between US and Korean patients treated with rivoceranib for recurrent or metastatic adenoid cystic carcinoma
Cancer Research and Treatment: Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
Gastric Cancer: Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
Liver Cancer: Impact of age on patient-reported outcomes with first-line camrelizumab plus rivoceranib versus sorafenib in adults with unresectable hepatocellular carcinoma: Post hoc analyses of the CARES-310 open-label, randomized, phase 3 trial
Clinical Pharmacokinetics: Effect of Rivoceranib 200 mg Once Daily on the Pharmacokinetics of a Cocktail Probe Substrate of Cytochrome P450 Enzymes: A Phase I Trial in Healthy Volunteers
